News

Study ADX10059-204 is a double-blind, placebo-controlled, multi-center European Phase IIb trial in about 90 gastroesophageal reflux disease (GERD) patients known to respond well to proton pump inhibitors (PPI).

This collaboration will allow the development of highly-targeted commercial information products and continuing medical education (CME) programs for physicians, based on aggregated, HIPAA-compliant patient information derived from individual

According to the company, the newly allowed claims include subject matter covering aspects of blood-based appendicitis testing. A notice of allowance generally completes the substantive examination of a

The Spirit small vessel trial is designed to study 250 patients at approximately 50 centers in the US. The primary endpoint is a composite measure of cardiac death,

The patent issued by the World Intellectual Property Organization covers a novel method for ApoE haplotyping using multiplex PCR. Seegene’s proprietary Dual Priming Oligonucleotide (DPO) technology is being

The synergy of RayBiotech’s innovative portfolio with SeraCare’s global reach and expertise in virology, serology, immunology and molecular biology supports the acceleration of biomedical research and product development,

Saint Maurice’s laboratories process 2,000 tests per day and include the following specialties: biochemistry, toxicology, hematology, microbiology and immunology. Twelve analyzers will be connected directly to EdgeLab via

The program consists of two Phase III clinical placebo-controlled trials, each enrolling approximately 320 patients. The two trials will enroll patients internationally at sites in Europe, the US,

According to Axis-Shield, Active-B12 is a more efficient method for detection of vitamin B12 deficiency compared to the measurement of total B12 in the blood, as it measures